Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Read about our new masking policy »

Treating the HER2 Pathway in Early and Advanced Breast Cancer HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA Pegram, M. D. 2013; 27 (4): 751-?

Abstract

ERBB2 gene amplification occurs in ~20% of human breast cancers (BC) and is associated with an adverse clinical prognosis, indicating that it may be playing a critical role in disease pathogenesis. Therapeutic strategies targeting pathologic ERBB2 overexpression have revolutionized the diagnosis and treatment of BC. Indeed, humanized anti-ERBB2 antibodies, small molecule ERBB2 kinase inhibitors and ERBB2-targeting antibody-drug conjugates have proven safety and efficacy based upon evidence from randomized phase III clinical trials. Recent progress in targeting ERBB2 alteration will be reviewed, with focus on data that has informed changes in clinical practice for the treatment of BC.

View details for DOI 10.1016/j.hoc.2013.05.007

View details for Web of Science ID 000323798000008

View details for PubMedID 23915743